TrialThe oncologist2018

Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial.

Benjamin L Maughan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.